All Stories

  1. Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites
  2. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature
  3. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
  4. Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort Study
  5. The prevalence and disease course of autoimmune liver diseases in Greenland
  6. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
  7. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
  8. The role of N‐terminal pro‐brain natriuretic peptide, chromogranin A, and 5‐hydroxyindoleacetic acid in screening for carcinoid heart disease
  9. Fungal translocation measured by serum 1,3‐ß‐D‐glucan correlates with severity and outcome of liver cirrhosis—A pilot study
  10. Editorial: non‐invasive diagnosis of alcohol‐related steatohepatitis in patients ongoing alcohol withdrawal based on cytokeratin 18 and transient elastography
  11. A nationwide study of autoimmune liver diseases in the Faroe Islands: Incidence, prevalence, and causes of death 2004 - 2021
  12. Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode
  13. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
  14. Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease
  15. The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis
  16. The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation
  17. The Prevalence of Inflammatory Bowel Disease in Greenland
  18. Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease
  19. Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours
  20. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding
  21. Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
  22. Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
  23. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease
  24. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance
  25. Fatigue and quality of life in patients with neuroendocrine neoplasia
  26. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients
  27. The presence of interferon affects the progression of non-alcoholic fatty liver disease
  28. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumours and differentiation from small intestinal neuroendocrine tumours
  29. 276-OR: Impaired Glucagon-Mediated Suppression of VLDL-TG Secretion in Individuals with MAFLD
  30. Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
  31. Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study
  32. Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center
  33. Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
  34. The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?
  35. The galactose elimination capacity test to monitor liver disease course in patients with Wilson’s disease
  36. Contacts to general practice in the 12 months preceding a diagnosis of an abdominal cancer: a national register-based cohort study
  37. Prognosis of Patients with Bronchopulmonary Neuroendocrine Neoplasms in a Tertiary Neuroendocrine Tumor Centre of Excellence
  38. Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
  39. Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
  40. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
  41. Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single‐Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent
  42. Cognitive impairment in stable Wilson disease across phenotype
  43. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis
  44. Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply
  45. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
  46. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults
  47. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension
  48. Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension
  49. Abdominal investigations in the year preceding a diagnosis of abdominal cancer: A register-based cohort study in Denmark
  50. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
  51. Cognitive Impairment In Stable Wilson Disease Across Phenotype.
  52. Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner
  53. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
  54. P316 Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNFα treatment response in Crohn’s disease
  55. Cancer suspicion, referral to cancer patient pathway and primary care interval: a survey and register study exploring 10 different types of abdominal cancer
  56. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
  57. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
  58. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
  59. Interferon lambda 4 genotype and pathway in alcoholic hepatitis
  60. Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease
  61. Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome – a nationwide cohort study
  62. No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation
  63. Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
  64. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study
  65. CELL-FREE DNA AND CLINICAL CHARACTERISTICS IN PATIENTS WITH SMALL INTESTINAL OR PANCREATIC NEUROENDOCRINE TUMORS
  66. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
  67. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data
  68. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
  69. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
  70. Macrophage markers and innate immunity in cirrhosis
  71. Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C
  72. First trimester biomarkers for prediction of gestational diabetes mellitus
  73. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
  74. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
  75. Combining Tissue and Circulating Tumor DNA Increases the Detection Rate of CTNNB1 Mutation in Hepatocellular Carcinoma
  76. Thrombophilia testing in patients with portal vein thrombosis
  77. One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
  78. A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations.
  79. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
  80. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
  81. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study
  82. The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men
  83. 1006P PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
  84. Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders
  85. Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis
  86. Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre
  87. Early-tips should be performed in high-risk cirrhotic patients despite the presence of hepatic encephalopathy at admission
  88. Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis
  89. A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors
  90. Clinical Efficacy of First and Second Series of Peptide Receptor Radionuclide Therapy in Patients With Neuroendocrine Neoplasm: A Cohort Study
  91. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
  92. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease
  93. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
  94. Liver-related effects of chronic hepatitis C antiviral treatment
  95. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy
  96. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute‐on‐chronic liver failure and acute decompensation
  97. Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701]
  98. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
  99. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease
  100. Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
  101. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease
  102. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
  103. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis
  104. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease
  105. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
  106. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
  107. New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report
  108. Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
  109. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
  110. Plasma chromogranin A (CgA) as a predictor of progression in patients with neuroendocrine tumors.
  111. Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C
  112. Use of complimentary medicines in patients with neuroendocrine tumors.
  113. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis
  114. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial
  115. Insulin resistance, liver inflammation and fibrosis in patients with NAFLD
  116. The macrophage‐related biomarkers sCD163 and sCD206 are released by different shedding mechanisms
  117. 551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING
  118. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study
  119. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose
  120. The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation
  121. Hepatic exposure of metformin in patients with non‐alcoholic fatty liver disease
  122. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
  123. FRI-339-Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis
  124. PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS
  125. THU-324-Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions
  126. PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding
  127. THU-325-Regional liver function investigated by galactose positron emission tomography is reduced in patients with non-alcoholic steatohepatitis
  128. SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients
  129. FRI-120-Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension
  130. FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis
  131. Effects of implementation of a national fast track clinical pathway for hepatocellular carcinoma in western Denmark
  132. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
  133. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions
  134. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark
  135. P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn’s disease
  136. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
  137. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study
  138. Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis
  139. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
  140. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease
  141. Urea cycle dysregulation in non-alcoholic fatty liver disease
  142. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study
  143. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
  144. The Risk of Second Primary Colorectal Adenocarcinomas is not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms – A Nationwide Population Based Study
  145. The role of IFN in the development of NAFLD and NASH
  146. β-Blockers Improve Presinusoidal Portal Hypertension
  147. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology
  148. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease
  149. The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals
  150. Soluble CD163 correlates with lipid metabolic adaptations in human type 1 diabetes patients during ketoacidosis
  151. Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients
  152. Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections
  153. Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure
  154. Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches
  155. Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome
  156. Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study
  157. The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
  158. The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality
  159. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease
  160. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
  161. Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood
  162. Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis
  163. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment
  164. Nutritional status and nutritional risk in patients with neuroendocrine tumors
  165. Cell death markers in patients with cirrhosis and acute decompensation
  166. Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination
  167. Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial
  168. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation
  169. The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients
  170. Corrigendum
  171. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study
  172. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
  173. Time course of compromised urea synthesis in patients with alcoholic hepatitis
  174. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
  175. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
  176. High burden of coronary atherosclerosis in patients with cirrhosis
  177. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease
  178. Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. Authors’ reply
  179. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors
  180. Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype-phenotype relationship
  181. Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment
  182. Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre
  183. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based study
  184. IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
  185. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
  186. Long-Term Ethanol Exposure Decreases the Endotoxin-Induced Hepatic Acute Phase Response in Rats
  187. Time Course of Compromised Urea Synthesis in Patients With Alcoholic Hepatitis
  188. Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease
  189. Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting
  190. Enrichment of genetic variants in the glucocorticoid receptor signalling pathway in standard treatment failure autoimmune hepatitis
  191. Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis
  192. Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson’s disease
  193. The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy
  194. The novel macrophage activation marker soluble Mannose Receptor, and soluble CD163, are elevated after acetaminophen intoxication in relation to liver disease severity
  195. Time course of compromised urea synthesis in patients with alcoholic hepatitis
  196. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls
  197. A descriptive cross-sectional study of pain in patients with neuroendocrine tumors
  198. Polymorphisms in the IL‐1 gene cluster influence systemic inflammation in patients at risk for acute‐on‐chronic liver failure
  199. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis
  200. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation
  201. Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer
  202. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury
  203. Role of macrophages and macrophage activation marker sCD163 in patients with autoimmune hepatitis
  204. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis
  205. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
  206. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure
  207. Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis
  208. The damage-associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation
  209. Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors’ reply
  210. Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children
  211. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease
  212. Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea
  213. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
  214. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)
  215. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
  216. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure
  217. Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment
  218. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
  219. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
  220. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
  221. Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats
  222. Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease
  223. Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
  224. Circulating CD36 Correlates with Intrahepatic Lipid Content in Non-Alcoholic Fatty Liver Disease Patients
  225. Disease-Related Variants in Genes Involved in Bile Formation and Transport Demonstrated in 12 of 22 Patients with “Unexplained Cholestasis” by the Use of a Novel Panel for Genetic Testing
  226. Liver Regeneration Capacity after Partial Hepatectomy in Rats with Non-Alcoholic Steatohepatitis
  227. Macrophage Activation Assessed by Soluble CD163 and Soluble Mannose Receptor is Associated with Liver Injury in Patients with Acetaminophen Overdose
  228. Patients with Liver Cirrhosis Have Similar Prevalence, but Higher Burden of Coronary Artery Disease Compared to Patients Evaluated for Angina Pectoris
  229. Polymorphismus in the Interleukin (IL)-1 Gene Cluster Influence the Inflammatory Burden in Patients with Decompensated Cirrhosis and Acute-On-Chronic Liver Failure
  230. Soluble CD163, a Marker of Macrophage Activation, is Increased in Early Allograft Dysfunction after Liver Transplantation
  231. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
  232. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma
  233. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
  234. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center
  235. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment
  236. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art
  237. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery
  238. Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System
  239. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis
  240. Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC: Associations with Risk Factors
  241. Effect of resveratrol on experimental non-alcoholic steatohepatitis
  242. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure
  243. Macrophage activation in obese children with non-alcoholic fatty liver diease
  244. P0974 : Effects of resveratrol on experimental non-alcoholic steatohepatitis
  245. P1044 : Randomised, placebo-controlled clinical trial: Long-term resveratrol treatment for non-alcoholic fatty liver disease
  246. P1061 : The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with non-alcoholic fatty liver disease
  247. LP21 : The macrophage activation markers soluble CD206 And CD163 predict mortality in patients with liver cirrhosis and acute-on-chronic liver failure (ACLF)
  248. Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
  249. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites
  250. Reply
  251. A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumours
  252. Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti-TNF-αAntibody Treatment in Active Inflammatory Bowel Disease
  253. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure
  254. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure
  255. Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study
  256. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
  257. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children
  258. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
  259. Vitamin B12and its binding proteins in hepatocellular carcinoma and chronic liver diseases
  260. Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function
  261. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C
  262. Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats
  263. P320 ALCOHOLIC HEPATITIS DECREASES THE CAPACITY FOR UREA SYNTHESIS
  264. P1018 MARKERS OF COLLAGEN REMODELING DETECT CLINICALLY SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS C PATIENTS
  265. P1007 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C
  266. P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
  267. Effects of long-acting somatostatin analogues on redox systems in rat lens in experimental diabetes
  268. Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease
  269. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease
  270. Trefoil factors in inflammatory bowel disease
  271. Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center
  272. Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease
  273. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion
  274. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience
  275. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
  276. 591 BACTERIAL DNA MEASUREMENTS IN PATIENTS WITH CIRRHOSIS UNDERGOING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION
  277. 1342 CHANGE IN SOLUBLE CD163, A MARKER OF ACTIVATED MACROPHAGES, IS ASSOCIATED WITH IMPROVEMENT IN LIVER ENZYMES AND METABOLIC PROFILE IN OBESE CHILDREN DURING LIFESTYLE INTERVENTION
  278. 1301 ENDOTOXIN CAUSES HIGH MORTALITY AND REDUCED HEPATIC SYNTHESIS OF ACUTE PHASE PROTEINS IN RATS WITH EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE
  279. 1414 THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF).
  280. Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver
  281. Macrophage biomarkers predict prognosis in patients with liver cirrhosis
  282. Regulation of urea synthesis during the acute-phase response in rats
  283. Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course
  284. Goblet Cell Carcinoids of the Appendix
  285. Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
  286. Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt
  287. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism
  288. Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study
  289. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional
  290. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
  291. Insulin-like Growth Factor-I Concentration and Risk of Prostate Cancer: Results from the European Prospective Investigation into Cancer and Nutrition
  292. Ischemic pre- and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/reperfusion
  293. Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis
  294. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis
  295. Effects of long-term experimental diabetes on adrenal gland growth and phosphoribosyl pyrophosphate formation in growth hormone-deficient dwarf rats
  296. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study
  297. 1371 IL-22 PRODUCING T CELLS ARE ASSOCIATED WITH A FAVOURABLE DISEASE COURSE IN ALCOHOLIC HEPATITIS
  298. 1375 PROGNOSIS OF ALCOHOLIC PURE STEATOSIS AND STEATOHEPATITIS: A NATIONWIDE BIOPSY- AND REGISTRY-BASED STUDY
  299. 723 SOLUBLE CD163, A MARKER FOR MACROPHAGE ACTIVATION, IS NOT ASSOCIATED TO HCC, PER SE BUT PREDICTS DISEASE PROGRESSION
  300. Carvedilol or propranolol in portal hypertension? A randomized comparison
  301. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition
  302. Effect of a 10-week Weight Loss Camp on Fatty Liver Disease and Insulin Sensitivity in Obese Danish Children
  303. Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes
  304. Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center
  305. Goblet Cell Carcinoid in a Patient with Neurofibromatosis Type 1: A Rare Combination
  306. Prognosis and staging of non-alcoholic fatty liver disease
  307. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors
  308. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS
  309. Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
  310. Effects of ischemic pre- and postconditioning on HIF-1α, VEGF and TGF-β expression after warm ischemia and reperfusion in the rat liver
  311. IL-6 has no acute effect on the regulation of urea synthesisin vivoin rats
  312. Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease
  313. Expression of genes involved in rat liver angiogenesis after ischaemia and reperfusion: effects of ischaemic pre- and post-conditioning
  314. Creation of a Fistula Between the Hepatic Duct and the Gastric Lumen by way of Percutaneus Transhepatic Cholangiography: A Case Report
  315. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children
  316. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC)
  317. Unchanged capacity of urea synthesis during acute phase response in rats
  318. Insulin sensitivity and body composition in cirrhosis: changes after TIPS
  319. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours
  320. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
  321. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum
  322. 169 CARVEDILOL OR PROPRANOLOL IN PORTAL HYPERTENSION? A RANDOMIZED CLINICAL TRIAL
  323. 514 CIRCULATING SCD163, A SCAVENGER RECEPTOR RELEASED FROM ACTIVATED MACROPHAGES, IS ASSOCIATED WITH PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS
  324. 586 IMAGING OF NEUROENDOCRINE TUMORS AND LIVER METASTASIS BY F18-DOPA PET SCANNING
  325. Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studies
  326. Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis
  327. Tumor necrosis factor-α acutely up-regulates urea synthesisin vivoin rats – a hepatic component of inflammatory catabolism?
  328. Partial Liver Ischemia Is Followed by Metabolic Changes in the Normally Perfused Part of the Liver during Reperfusion
  329. Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections
  330. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats
  331. The Association between Diet and Serum Concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition
  332. 752 EFFECT OF TIPS ON SOLUBLE CD163 IN PATIENTS WITH LIVER CIRRHOSIS
  333. 159 EFFECTS OF ISCHEMIC PRE- AND POSTCONDITIONING ON HIF-1α, VEGF AND TGF-β EXPRESSION DURING WARM LIVER ISCHEMIA AND REPERFUSION
  334. 194 INSULIN SENSITIVITY AND BODY COMPOSITION IN CIRRHOSIS: CHANGES AFTER TIPS
  335. 99 RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH LIVER DISEASE: A NATIONWIDE POPULATION- BASED CASE-CONTROL STUDY
  336. 252 TUMOR NECROSIS FACTOR-ALPHA ACUTELY UP-REGULATES UREA SYNTHESIS IN VIVO IN RATS – A HEPATIC ELEMENT OF INFLAMMATORY CATABOLISM
  337. The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis
  338. Cytokine Changes during Warm Ischemia and Reperfusion of the Pig Liver with or without Preconditioning
  339. Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study
  340. The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis
  341. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes
  342. sMAC in plasma and ascites from patients with liver cirrhosis
  343. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study
  344. Soluble CD163 from activated macrophages predicts mortality in acute liver failure
  345. Metabolic Changes in the Pigliver During Warm Ischemia and Reperfusion Measured by Microdialysis
  346. 3530 POSTER Preliminary results from GEPTOSIS, the international study on medical treatment practice and outcomes in gastroenteropancreatic (GEP) neuroendocrine tumors (NET): variability in the time between initial diagnosis and treatment of GEP NET
  347. Portal vein thrombosis; risk factors, clinical presentation and treatment
  348. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition
  349. Impact of Enteral Supplements Enriched with ω–3 Fatty Acids and/or ω–6 Fatty Acids, Arginine and Ribonucleic Acid Compounds on Leptin Levels and Nutritional Status in Active Crohn’s Disease Treated with Prednisolone
  350. Opposite effects on regulation of urea synthesis by early and late uraemia in rats
  351. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn’s disease: Relations to disease activity and corticosteroid treatment
  352. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention
  353. Effects of five different alcoholic drinks on patients with Crohn's disease
  354. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition
  355. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease
  356. Serum Trefoil Factors in Patients with Inflammatory Bowel Disease
  357. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women
  358. Quality improvement in wellness reports in patients with Crohn’s disease
  359. Discharge diagnoses of liver diseases in Nuuk Greenland compared to a Danish county hospital
  360. Associations between the IGF system and inflammatory markers in inflammatory bowel disease
  361. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids
  362. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis
  363. The Insulin-Like Growth Factor System and Markers of Inflammation in Adult Patients with Inflammatory Bowel Disease
  364. Effects of pure ethanol and alcopops on glucose, insulin, and the insulin-like growth factor system in healthy subjects
  365. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids
  366. The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease
  367. The Influence of Amphotericin B and Neomycin on the Effect of Human Relaxin-2 on Foetal Membranes and Isolated Myometrium
  368. Budd‐Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto‐systemic shunt
  369. Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis
  370. Albumin in vaginal fluid is a marker of infection in early pregnancy
  371. Editorial
  372. Effect of Combination Therapy with a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor on Renal Hypertrophy and Urinary Albumin Excretion in Diabetic Rats
  373. Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults
  374. Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice
  375. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment
  376. Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis
  377. Lessons Learned From Lymphocytes: CC Chemokine Receptor-7 Involved in Lymphogenic Metastasis of Melanoma
  378. Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity
  379. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor β receptor expression in experimental diabetes in rats
  380. Inhibition of Major Histocompatibility Complex Class II-Dependent Antigen Presentation by Neutralization of Gamma Interferon Leads to Breakdown of Resistance against Measles Virus-Induced Encephalitis
  381. Comparison of the effects of nitrendipine and enalapril on development and progression of diabetic glomerulopathy in streptozotocin-diabetic rats
  382. Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats
  383. Serum markers for hepatic fibrosis in chronic hepatitis C
  384. The Renal Expression of Transforming Growth Factor-  Isoforms and Their Receptors in Acute and Chronic Experimental Diabetes in Rats
  385. Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion
  386. The Calcium Channel Blocker Nitrendipine Attenuates Renal and Glomerular Hypertrophy in Diabetic Rats
  387. Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats
  388. Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding proteins, and renal growth following unilateral nephrectomy in rats
  389. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats
  390. Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoid
  391. Diabetic kidney disease: the role of growth factors
  392. Herpesvirus Saimiri Transforms Human T-Cell Clones to Stable Growth without Inducing Resistance to Apoptosis
  393. Differential expression of renal growth hormone receptor and its binding protein in experimental diabetes mellitus
  394. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes
  395. The Role of Growth Hormone, Insulin-Like Growth Factors, Epidermal Growth Factor and Transforming Growth Factor β in Diabetic Kidney Disease: An Update
  396. Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats
  397. Changes in Facilitative Glucose Transporter Messenger Ribonucleic Acid Levels in the Diabetic Rat Kidney
  398. Effect of graded renal ablation on kidney and serum insulin-like growth Factor-I (IGF-I) and IGF binding proteins in rats: Relation to compensatory renal growth
  399. The Role of Growth Factors in Diabetic Kidney Disease
  400. Increased number of myocardial voltage-gated Ca2+ channels and unchanged total  -receptor number in long-term streptozotocin-diabetic rats
  401. Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats
  402. The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease
  403. Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention
  404. Effect of Diabetes and Dietary Ubiquinone Supplementation on the Post-translational Modification of Rat Lens βL Crystallin
  405. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes.
  406. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes
  407. Effect of sodium selenite on growth, insulin-like growth factor-binding proteins and insulin-like growth factor-I in rats
  408. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
  409. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
  410. Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. A preliminary study
  411. Roles of Growth Factors in Diabetic Kidney Disease
  412. Selenium in the central nervous system of rats exposed to 75-Sel-selenomethionine and sodium selenite
  413. Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes
  414. Selenium complexes in the anterior pituitary of rats exposed to L-selenomethionine